Neumora Therapeutics IPO Presentation Deck

Precision strategy for NMRA-CK18 in Amyotrophic Lateral Sclerosis (ALS) incorporates drug specific properties to define potential best responders AALS data set Incorporating machine learning mediated ALS patient clustering from the Answer ALS (AALS) data set with NMRA-CK10 transcriptomic drug signature enriches for subpopulations distinct patient populations Unsupervised clustering of the AALS data set shows patient heterogeneity with little distinction MVAE Unsupervised MVAE Clustering 45 14 Distance 11 Unsupervised Cluster Proximity to NMRA-CK10 drug signature *MVAE: Multimodal Variational Autoencoder NMRA-CK10 induced gene expression change Grouped by biological function Supervised clustering with the NMRA-CK18 drug signature and enhances precision identifying distinct patient groups within the ALS patient population ▬▬▬▬▬▬ CK10 substrate genes 1-statistic (compound effect) AALS data set MVAE 01 DO D.D Knowledge-Based MVAE Clustering 0.5 Characterizing more homogeneous patient populations has the potential to enable more targeted, biomarker driven clinical development plans 10 15 Knowledge Based Cluster M Confidential 20 Distance Proximity to NMRA-CK10 drug signature C 23

View entire presentation